Document text
Principal Investigator: KATHLEEN E. RODGERS
Organization: UNIVERSITY OF ARIZONA
Fiscal Year: 2020
Award: $1,533,089
Funding agency: National Institute on Aging
PROJECT SUMMARY/ABSTRACT
Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide,
and is the most common dementia of late-life. To date, no interventions have demonstrated substantial
therapeutic efficacy to prevent, delay or treat AD. In recent years, both cardiovascular disorders (CVD) and
genetic factors (ApoE4) have been attributed to an increased risk of developing AD. The pathological arm of the
Renin Angiotensin System (RAS) has been implicated in both CVD and AD, whereas the protective arm,
including Angiotensin (1-7)[A(1-7)], Mas receptor and ACE2 are known to counter-regulate these effects. A(1-
7), through the Mas receptor, is known to reduce inflammation and oxidative (OS) in several disease states and
it also has regenerative effects by upregulating endogenous stem cell populations. Data from clinical studies
have shown that both A(1-7) and ACE2 are reduced in AD patients and several in-vivo studies support the
efficacy of A(1-7) in treating AD. While the effects of A(1-7) in AD models have been extremely promising, its
short half-life and lack of oral bioavailability make it challenging to develop as a therapeutic modality. In order to
overcome this shortcoming, our lab has developed an equipotent small molecule analogues of A(1-7),
RASRx1902 and RASRx1911. RASRx1902 and RASRx1911 have been shown to reduce inflammation and OS
in target organs as well as having a regenerative effect on damaged tissues. A recent study from our lab showed
that RASRx1902 and RASRx1911 were able to improve cognitive function as well as reduce OS in the brain in
a mouse model of hypertension induced cognitive dysfunction (transverse aortic constriction [TAC]). Since Mas
agonism is known to have a beneficial effect in AD, we hypothesize that these molecules can be developed as
a potential new therapeutic for the treatment of AD and related dementias. The primary objective of this proposal
are to advance development of one small molecule Mas agonist to submission of an Investigation New Drug
Application (IND) for the treatment of AD and related dementias through: 1. Evaluation of the oral efficacy of
RASRx1902 and RASRx1911 in TAC and AD mouse models (5xFAD & ApoE4); 2. Assessment of the efficacy
of RASRx1902 in TAC-ApoE4 mice, 3. Scale up of one Mas agonist manufactured under Good Manufacturing
Practices (GMP); 4. Development of a formulation of one Mas agonist for Phase I clinical trial; 5. Completion of
ADME, (PK) and IND-enabling Toxicology studies; 6. Preparation Pre IND and IND Documentation; 7. Conduct
of a Pre IND meeting; and 8. Filing of an IND. Research proposed herein is responsive to PAS 18-820 to develop
and evaluate therapies “that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and
behavioral symptoms”.
Terms: <AD dementia><AD model><AD pathology><AD related dementia><ADRD><APOE e4><APOE-ε4><APOEε4><Advanced Development><Affect><Age><Agonist><Alzheimer><Alzheimer Type Dementia><Alzheimer disease><Alzheimer related dementia><Alzheimer risk factor><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's disease dementia><Alzheimer's disease model><Alzheimer's disease pathology><Alzheimer's disease patient><Alzheimer's disease related dementia><Alzheimer's disease risk><Alzheimer's pathology><Alzheimer's patient><Alzheimers Dementia><Alzheimers disease><Amentia><Angiotensin AT1 Receptor><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Angiotensin II Type 1 Receptor><Angiotensins><Animal Model><Animal Models and Related Studies><Behavioral Symptoms><Bioavailability><Bioavailable><Biologic Availability><Biological Availability><Blood Serum><Body Tissues><Booklets><Brain><Brain Nervous System><Brochures><CD143 Antigens><Canine Species><Canis familiaris><Carboxycathepsin><Cardiovascular Diseases><Cerebrovascular Circulation><Chemistry><Chronic><Clinical><Clinical Data><Clinical Protocols><Clinical Research><Clinical Study><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive Manifestations><Cognitive Symptoms><Cognitive decline><Cognitive function abnormal><Common Rat Strains><Data><Dementia><Development><Dipeptidyl Peptidase A><Disease><Disorder><Disturbance in cognition><Documentation><Dogs><Dogs Mammals><Dose><Drugs><Early-Stage Clinical Trials><Elderly><Encephalon><Enzyme Gene><Enzymes><Evaluation><Formulation><Frequencies><Generations><Genetic><Goals><Half-Life><Hypertension><Impaired cognition><Incidence><Inflammation><Inflammatory><Intervention><Intervention Strategies><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Kininase A><Kininase II><Link><Medication><Memory Loss><Mesenchymal><Methodology><Mice><Mice Mammals><Modality><Modeling><Murine><Mus><NIH RFA><Neurobehavioral Manifestations><Neurobehavioral Signs and Symptoms><Neuronal Dysfunction><Operative Procedures><Operative Surgical Procedures><Oral><Organ><Oxidative Stress><PK/PD><Pamphlets><Pathogenesis><Pathologic><Pathology><Pathway interactions><Patients><Peptidyl-Dipeptidase A><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacology><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Physiologic Availability><Play><Preparation><Primary Senile Degenerative Dementia><Rat><Rats Mammals><Rattus><Receptor Protein><Receptor, Angiotensin, Type 1><Renin-Angiotensin System><Reporting><Request for Applications><Research><Research Design><Risk><Rodent Model><Role><Route><Serum><Signal Pathway><Study Type><Surgical><Surgical Interventions><Surgical Procedure><Systemic disease><Testing><Therapeutic><Tissues><Toxicology><Treatment Efficacy><Validation><Vascular Hypertensive Disease><Vascular Hypertensive Disorder><advanced age><ages><alzheimer model><alzheimer risk><analog><apo E-4><apo E4><apo epsilon4><apoE epsilon 4><apoE-4><apoE4><apolipoprotein E epsilon 4><apolipoprotein E-4><apolipoprotein E4><arm><brain blood flow><canine><cardiovascular disorder><cerebral blood flow><cerebral circulation><cerebral vascular><cerebro-vascular><cerebrocirculation><cerebrovascular><cerebrovascular blood flow><clinical development><cognitive dysfunction><cognitive function><cognitive loss><constriction><dementia of the Alzheimer type><developmental><domestic dog><drug/agent><elders><endothelial progenitor cell><endothelial stem cell><geriatric><global health><high blood pressure><high risk><hyperpiesia><hyperpiesis><hypertensive disease><improved><in vivo><intervention efficacy><interventional strategy><late life><later life><meetings><memory decline><model of animal><model organism><mouse model><murine model><neural dysfunction><neurobehavioral symptom><neuroinflammation><neuroinflammatory><new approaches><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel approaches><novel drug treatments><novel drugs><novel strategies><novel strategy><novel therapeutics><novel therapy><older adult><older person><pathway><pharmacokinetics and pharmacodynamics><phase I protocol><pre-clinical study><preclinical study><prevent><preventing><primary degenerative dementia><receptor><regenerative><scale up><senile dementia of the Alzheimer type><senior citizen><sex><small molecule><social role><stability testing><stem cell population><study characteristics><study design><surgery><therapeutic efficacy><therapeutically effective><therapy efficacy>